Apellis Pharmaceuticals, Inc. (APLS)
20.96
-0.68
(-3.14%)
USD |
NASDAQ |
Feb 27, 16:00
20.36
-0.60
(-2.86%)
After-Hours: 07:28
Apellis Pharmaceuticals Research and Development Expense (Annual) : 295.85M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ultragenyx Pharmaceutical, Inc. | 723.00M |
| Amneal Pharmaceuticals, Inc. | 186.18M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| BioMarin Pharmaceutical, Inc. | 700.97M |
| Amicus Therapeutics, Inc. | 135.84M |